The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

After 72 weeks of treatment, people taking Zepbound lost about 50 pounds, compared with 33 pounds for those taking Wegovy. The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight ...

Getting access to popular weight loss drugs will be simpler and cheaper for some.Health insurer Cigna (CI) announced a new deal for copay caps on Eli Lilly (LLY) and Novo Nordisk (NVO) weight loss ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines.